Reuters: Regulatory News: Pfizer gets new rebuff from UK cost body for cancer drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Pfizer gets new rebuff from UK cost body for cancer drug Mar 28th 2013, 00:01 LONDON, March 28 | Wed Mar 27, 2013 8:01pm EDT LONDON, March 28 (Reuters) - Pfizer suffered a second rejection in two days from Britain's health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service. The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources. The decision follows a similar rebuff for Pfizer's lung cancer drug Xalkori on Wednesday. In both cases, the NICE recommendations are preliminary and subject to further consultation.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions